Brian Park, PharmD, Author at Ophthalmology Advisor

Kimmtrak Approved for Unresectable or Metastatic Uveal Melanoma

By

March 25, 2022

The approval was based on data from the phase 2 IMCgp100-202 trial that assessed Kimmtrak in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.

Cornea & Ocular Surface

Pataday Once Daily Relief Extra Strength Available Over-the-Counter

By

Brian Park, PharmD

March 25, 2021

Pataday Once Daily Relief Extra Strength is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.

Dry Eye

New Lubricant Eye Drops Help With Eye Dryness Related to Screen Use

By

Brian Park, PharmD

March 11, 2021

Refresh Digital is designed to protect tears from evaporating due to incomplete blinking during digital device use.

General Ophthalmology

NDA Submitted for MydCombi, a Novel Mydriatic Agent

By

Brian Park, PharmD

January 11, 2021

The NDA submission is supported by data from the phase 3 MIST-1 and MIST-2 studies.

Neuro-ophthalmology

Nerivio Device Cleared for Use in Patients With Chronic Migraine

By

Brian Park, PharmD

November 3, 2020

Previously, the device had only been approved in those with episodic migraine.

Retina & Vitreous

Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease

By

Brian Park, PharmD

October 29, 2020

The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.

Diabetic Eye Disease, Retina & Vitreous, Systemic Ophthalmology

EyeArt Autonomous AI System Cleared for Diabetic Retinopathy Screening

By

Brian Park, PharmD

September 10, 2020

EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.

Zimura Gets Fast Track Status for Geographic Atrophy Secondary to Dry AMD

By

Brian Park, PharmD

September 9, 2020

The FDA has granted Fast Track designation to Zimura (avacincaptad pegol; Iveric Bio) for the treatment of geographic atrophy secondary to dry age-related macular degeneration.

Retina & Vitreous

Brolucizumab Safety Update Issued Following Reports of Ocular Events

By

Brian Park, PharmD

September 8, 2020

Cases of severe vision loss, inflammation, and potential retinal vasculitis following treatment with Beovu (brolucizumab) injection are currently being investigated by the product’s manufacturer Novartis.

Cornea & Ocular Surface

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis

By

Brian Park, PharmD

September 8, 2020

Cystinosis is a rare, multisystem genetic disorder caused by an accumulation of cystine crystals throughout the body, including the eyes.

Brian Park, PharmD

All articles by Brian Park, PharmD

Kimmtrak Approved for Unresectable or Metastatic Uveal Melanoma

Pataday Once Daily Relief Extra Strength Available Over-the-Counter

New Lubricant Eye Drops Help With Eye Dryness Related to Screen Use

NDA Submitted for MydCombi, a Novel Mydriatic Agent

Nerivio Device Cleared for Use in Patients With Chronic Migraine

Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease

EyeArt Autonomous AI System Cleared for Diabetic Retinopathy Screening

Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis

Dry Eye Disease, Food Allergies Linked to Dupilumab-Induced Ocular AEs in Patients With AD